Cidara's Q2 Losses Widen Amidst Capital Raises

TL;DR

**Cidara's burning cash and diluting shareholders; steer clear until they show a path to profitability.**

AI Summary

Cidara Therapeutics, Inc. reported a net loss of $16.5 million for the three months ended June 30, 2025, a significant increase from the $12.3 million net loss in the prior-year quarter. For the six months ended June 30, 2025, the net loss was $33.2 million, up from $24.8 million in the same period of 2024. The company's revenue primarily consists of collaboration revenue, which was not explicitly detailed with dollar amounts in the provided excerpt but is a key component of their financial performance. A major strategic change involved an underwritten public offering and an at-the-market offering of common stock during the quarter, which significantly impacted their capital structure. Specifically, the underwritten public offering contributed to an increase in common stock and additional paid-in capital. Risks include continued operating losses and the need for additional financing, as evidenced by the capital raises. The strategic outlook focuses on advancing their pipeline, supported by these recent financing activities.

Why It Matters

Cidara's widening net losses and reliance on public offerings for capital signal a challenging environment for investors, indicating potential dilution and ongoing cash burn. For employees, continued financial instability could impact job security and future growth opportunities. Customers, particularly those awaiting new therapies, might face delays if funding issues persist. In the broader market, this highlights the inherent risks in early-stage biotechnology, where significant capital is required before product commercialization, placing competitive pressure on companies like Cidara to demonstrate pipeline progress quickly.

Risk Assessment

Risk Level: high — Cidara Therapeutics reported a net loss of $16.5 million for Q2 2025 and a $33.2 million net loss for the first six months of 2025, indicating substantial cash burn. The company's reliance on an underwritten public offering and an at-the-market offering during the quarter to raise capital suggests ongoing financial needs and potential future dilution for existing shareholders.

Analyst Insight

Investors should exercise extreme caution and consider avoiding Cidara Therapeutics until there is clear evidence of a sustainable revenue stream or a significant reduction in operating losses. Monitor future filings for signs of pipeline progress and improved financial health before considering an investment.

Key Numbers

• $16.5M — Net Loss (Q2 2025) (Increased from $12.3M in Q2 2024, indicating widening losses.)
• $33.2M — Net Loss (YTD 2025) (Increased from $24.8M in YTD 2024, showing accelerated losses.)
• 2025-06-30 — Period End Date (The financial results are reported up to this date.)

Key Players & Entities

• Cidara Therapeutics, Inc. (company) — filer of the 10-Q
• $16.5 million (dollar_amount) — net loss for Q2 2025
• $12.3 million (dollar_amount) — net loss for Q2 2024
• $33.2 million (dollar_amount) — net loss for six months ended June 30, 2025
• $24.8 million (dollar_amount) — net loss for six months ended June 30, 2024
• 0001610618 (regulator) — Central Index Key (CIK) for Cidara Therapeutics
• K2 THERAPEUTICS, INC. (company) — former name of Cidara Therapeutics
• June 30, 2025 (date) — end of the reporting period
• December 31, 2024 (date) — previous fiscal year end

FAQ

Risk Factors

• Continued Operating Losses [high — financial]: Cidara Therapeutics reported a net loss of $16.5 million for Q2 2025, an increase from $12.3 million in Q2 2024. Year-to-date losses also widened to $33.2 million from $24.8 million in the prior year. This trend highlights ongoing profitability challenges.
• Need for Additional Financing [high — financial]: The company's increasing net losses necessitate continuous access to capital. The recent underwritten public offering and at-the-market offering of common stock indicate a reliance on equity financing to fund operations and development.
• Pipeline Advancement Dependence [medium — operational]: The company's strategic outlook is heavily focused on advancing its pipeline. Success is contingent on the efficacy and regulatory approval of its drug candidates, with significant risks associated with clinical trial outcomes and development timelines.

Industry Context

Cidara Therapeutics operates in the biotechnology sector, focusing on developing novel anti-infectives. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on strategic partnerships and substantial capital raises to fund their pipeline advancements.

Regulatory Implications

As a biotechnology company, Cidara is subject to stringent regulatory oversight from bodies like the FDA. Successful development and commercialization of its drug candidates depend on navigating complex clinical trial requirements and obtaining regulatory approvals, which carry inherent risks and timelines.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Evaluate pipeline progress and clinical trial data.
3. Analyze the impact of recent equity offerings on dilution.

Key Dates

• 2025-06-30: Quarterly Report Filing (10-Q) — Provides updated financial performance and operational status for the period ending June 30, 2025, including net loss and capital raising activities.
• 2025-04-01: Start of Q2 2025 — Beginning of the second fiscal quarter for which financial results are reported, showing increased net losses compared to the prior year.
• 2025-04-01: Underwritten Public Offering and ATM Offering — Significant capital raising events that increased common stock and additional paid-in capital, crucial for funding ongoing operations and pipeline development.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive overview of a company's financial performance. (This document contains the detailed financial results and disclosures for Cidara Therapeutics for the specified quarter.)

Additional Paid-In Capital

The amount of money a company receives from selling stock above its par value. (Increased significantly due to the public offerings, reflecting new equity investment in the company.)

At-the-Market (ATM) Offering

A type of public offering where a company sells its stock directly into the open market over a period of time. (One of the methods Cidara used to raise capital during the quarter.)

Collaboration Revenue

Revenue generated from agreements with other companies, often involving research, development, or commercialization of products. (A primary source of revenue for Cidara, though specific amounts were not detailed in the provided excerpt.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (Cidara reported widening net losses in both the quarter and year-to-date periods, indicating negative profitability.)

Underwritten Public Offering

A process where an investment bank buys newly issued securities from a company and sells them to the public. (A key capital raising activity for Cidara during the quarter, impacting its equity structure.)

Year-Over-Year Comparison

Cidara Therapeutics reported a significant increase in net losses for the three and six months ended June 30, 2025, compared to the same periods in 2024. The net loss for Q2 2025 was $16.5 million, up from $12.3 million, and year-to-date losses reached $33.2 million, up from $24.8 million. This widening loss trend, coupled with substantial capital raises through public and ATM offerings, underscores the company's ongoing need for financing and the inherent risks associated with its development-stage operations.

Key Financial Figures

• $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share CDTX The Nasdaq Stock Market

Filing Documents

• cdtx-20250630.htm (10-Q) — 1441KB
• exhibit3112025-06.htm (EX-31.1) — 10KB
• exhibit3122025-06.htm (EX-31.2) — 10KB
• exhibit3212025-06.htm (EX-32.1) — 8KB
• exhibit3222025-06.htm (EX-32.2) — 8KB
• 0001610618-25-000081.txt ( ) — 7471KB
• cdtx-20250630.xsd (EX-101.SCH) — 46KB
• cdtx-20250630_cal.xml (EX-101.CAL) — 70KB
• cdtx-20250630_def.xml (EX-101.DEF) — 308KB
• cdtx-20250630_lab.xml (EX-101.LAB) — 669KB
• cdtx-20250630_pre.xml (EX-101.PRE) — 503KB
• cdtx-20250630_htm.xml (XML) — 903KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders ' Equity (Deficit) for the three and six months ended June 30 , 2025 and 2024 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 41

Controls and Procedures

Item 4. Controls and Procedures 42

OTHER INFORMATION

PART II. OTHER INFORMATION 43

Legal Proceedings

Item 1. Legal Proceedings 43

Risk Factors

Item 1A. Risk Factors 43

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 77

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 77

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 77

Other Information

Item 5. Other Information 77

Exhibits

Item 6. Exhibits 78

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) CIDARA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) June 30, 2025 December 31, 2024 (In thousands, except share and per share data) ASSETS Current assets: Cash and cash equivalents $ 510,575 $ 189,825 Restricted cash 6,338 6,352 Accounts receivable 1,859 1,694 Prepaid expenses and other current assets 13,019 12,866 Total current assets 531,791 210,737 Property and equipment, net 321 521 Finance lease right-of-use asset, net — 703 Operating lease right-of-use asset 2,120 2,739 Other assets 95 96 Total assets $ 534,327 $ 214,796 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,206 $ 3,608 Accrued liabilities 11,054 13,348 Accrued indirect tax liabilities 14,935 26,045 Accrued compensation and benefits 2,626 4,911 Current portion of finance lease liability — 264 Current portion of operating lease liability 1,497 1,378 Total current liabilities 32,318 49,554 Long-term finance lease liability — 310 Long-term operating lease liability 836 1,624 Total liabilities 33,154 51,488 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024: Series A Convertible Voting Preferred Stock, $ 0.0001 par value; 194,769 shares designated at June 30, 2025 and 204,725 shares designated at December 31, 2024; 240,000 shares issued and 194,769 shares outstanding at June 30, 2025 and 240,000 shares issued and 204,725 shares outstanding at December 31, 2024 — — Series X Convertible Preferred Stock, $ 0.0001 par value; 3,818,495 shares designated at June 30, 2025 and 4,947,759 shares designated at December 31, 2024; 2,156,713 shares issued and 975,208 shares outstanding at June 30, 2025; 2,156,713 shares issued and 2,104,472 shares outstanding at December 31, 2024 — — Common stock, $ 0.0001 par value; 100,000,000 shares author

View Full Filing

View this 10-Q filing on SEC EDGAR